These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20647696)

  • 1. [Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer].
    Hashimoto K; Tamura K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1187-91. PubMed ID: 20647696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
    Mercier-Vogel L; Bodmer A; Castiglione M
    Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA in breast cancer: from risk assessment to therapeutic prediction.
    Diamond JR; Borges VF; Eckhardt SG; Jimeno A
    Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
    Linn SC; Van 't Veer LJ
    Eur J Cancer; 2009 Sep; 45 Suppl 1():11-26. PubMed ID: 19775601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    Al-Ejeh F; Shi W; Miranda M; Simpson PT; Vargas AC; Song S; Wiegmans AP; Swarbrick A; Welm AL; Brown MP; Chenevix-Trench G; Lakhani SR; Khanna KK
    J Nucl Med; 2013 Jun; 54(6):913-21. PubMed ID: 23564760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors in breast cancer: BRCA and beyond.
    Rios J; Puhalla S
    Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibition in breast cancer.
    Garber J
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):573-5. PubMed ID: 20020667
    [No Abstract]   [Full Text] [Related]  

  • 10. PARP inhibitors: will the new class of drugs match the hype?
    Tuma RS
    J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
    Jones P; Altamura S; Boueres J; Ferrigno F; Fonsi M; Giomini C; Lamartina S; Monteagudo E; Ontoria JM; Orsale MV; Palumbi MC; Pesci S; Roscilli G; Scarpelli R; Schultz-Fademrecht C; Toniatti C; Rowley M
    J Med Chem; 2009 Nov; 52(22):7170-85. PubMed ID: 19873981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's PARPing up for triple-negative breast cancer?
    Sledge GW
    Clin Breast Cancer; 2009 Aug; 9(3):139. PubMed ID: 19661035
    [No Abstract]   [Full Text] [Related]  

  • 20. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
    Petrelli F; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.